Old Well Partners’s VYNE Therapeutics VYNE Stock Holding History

Old Well Partners’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-622	Closed	-$74K	–	51
2020 Q3	$74K	Buy	622 +369	+146%	+$43.1K	0.07%	35
2020 Q2	$31K	Buy	+253	New	+$34.3K	0.02%	28

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Old Well Partners's VYNE Position: Q4 2020 in Review

Old Well Partners sold out of VYNE Therapeutics (VYNE) in Q4 2020, closing a stake of 622 shares — an estimated $74K sold.

Old Well Partners first reported a position in VYNE in Q2 2020 and held it in 2 quarters. The position peaked at $74K in Q3 2020. 104 funds tracked by Wall St. Rank hold VYNE as of Q4 2020.

Old Well Partners reported no remaining VYNE Therapeutics position as of Q4 2020 after selling out during the quarter.
Old Well Partners sold 622 VYNE Therapeutics shares in Q4 2020, an estimated $74K.
Old Well Partners first reported a position in VYNE Therapeutics in Q2 2020 and held it in 2 quarters.
Old Well Partners's VYNE Therapeutics position peaked at $74K in Q3 2020.
104 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2020.

Based on Old Well Partners's 13F filing for Q4 2020, filed 16 Feb 2021.